Navigation Links
Cylene to Present Advances with Industry's Only Clinical CK2 Inhibitor, CX-4945, at EORTC-NCI-AACR
Date:11/16/2010

SAN DIEGO, Nov. 16, 2010 /PRNewswire/ -- Cylene Pharmaceuticals, Inc. will present advances in the development of their first-in-class, CK2 inhibitor CX-4945, at the 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics, to be held on November 16-19 in Berlin, Germany. CX-4945 is the first and only CK2 inhibitor to have entered clinical trials and represents an exciting new approach for the treatment for many different cancers. Three poster presentations will reveal results from the Phase I clinical trial and highlight the potential of this novel compound for combination anticancer therapies.

"We are delighted to be exhibiting so much fresh science around our flagship compound CX-4945. These scientific disclosures complement our manuscript describing the mechanism of action of CX-4945, recently accepted by the journal Cancer Research. Presentations by Cylene at premier conferences and the publication of our science by peer reviewed journals further validate CK2 as target for anticancer therapy," stated William Rice, PhD, President and CEO of Cylene Pharmaceuticals. "At the EORTC conference we will showcase the latest clinical data from patients treated with CX-4945 and also the discoveries concerning the critical roles that CK2 plays in the DNA Damage Response and EGF-Receptor pathways. These data provide a strong mechanistic rationale for the combination of CX-4945 with many agents that target these same pathways for the treatment of multiple cancers. As a company we aim to fully exploit the potential of CX-4945 in the clinic and ultimately see that it translates to real benefit for those patients and families struggling with cancer."

The presentation schedule is:

Wednesday, November 17, 2010: 12:00 PM Combined inhibition of EGFR and protein kinase CK2 synergistically blocks phosphorylation of ribosomal protein S6, induces apoptosis in cancer cells and displays enhanced antitumor activity in xenograft models - Molecular-targeted therapies-preclinical, Abstract 99, Poster Board 056

Thursday, November 18, 2010: 12:00 PM Clinical pharmacokinetics and pharmacodynamics of CX-4945, a novel inhibitor of protein kinase CK2: Interim report from the Phase I clinical trial - Molecular-targeted therapies-clinical trials, Abstract 414, Poster Board 155

Friday, November 19, 2010: 8:00 AM CX-4945, an inhibitor of protein kinase CK2, disrupts DNA damage repair, potentiates apoptosis and enhances antitumor activity of gemcitabine in a model of ovarian cancer - DNA repair and inhibitors, Abstract 518, Poster Board 054

About CK2 and CX-4945

Protein kinase CK2 has emerged as a validated drug target for cancer therapy due to its dysregulation andoverexpression in tumors and its regulatory roles in cell cycle control, DNA damage repair, and in the PI3K/Akt, Wnt and NFκB signaling cascades. CX-4945 is a potent and highly selective, small molecule inhibitor of CK2 and is currently under evaluation as an orally administered single agent in a Phase I clinical trial in patients with solid tumors (including breast, prostate, pancreatic cancers and inflammatory breast cancer, as well as multiple myeloma and Castleman's Disease). During this trial, CX-4945 has established favorable pharmacokinetic, pharmacodynamic and safety profiles. Measurement of mechanism and tumor-related biomarkers in patients reveal that CX-4945 hits the CK2 target and down-modulates the PI3K/Akt pathway. The pharmacokinetic and biomarker data demonstrate that CX-4945 is achieving pharmacologically active levels in plasma and in tumor cells and elicits a clear pharmacodynamic response in humans. Together, the findings establish CX-4945 as a promising therapeutic agent for targeting multiple cancers.

About Cylene Pharmaceuticals

Cylene Pharmaceuticals, Inc. is a San Diego-based, private biotechnology company discovering and developing targeted small molecule drugs to treat life-threatening cancers. Cylene's drug discovery platform, STAND (Selective TArgeting of Non-Oncogene Networks in Disease), has delivered a diverse portfolio of drug candidates that target the multiple pathways critical for the support and maintenance of cancer cells and that address unmet medical needs with substantial markets. Cylene's novel agents include oral inhibitors of the cancer-linked serine/threonine protein kinases (CK2 and Pim), as well as oral agents that activate p53 via modulation of RNA Polymerase I activity in the upstream ribosome biogenesis pathway. Cylene's innovative platform enables the rapid discovery of first-in-class agents that exert antitumor activity as a single agent and that can mechanistically enhance the effectiveness of current cancer therapies. For more information on Cylene and its programs, please visit www.cylenepharma.com.


'/>"/>
SOURCE Cylene Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cylene to Present Advances in its Oral Inhibitor of CK2 at AACR Annual Meeting
2. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
3. Questcor to Present at the Maxim Group Growth Conference
4. Medco to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
5. Warner Chilcott to Present at the Bank of America Merrill Lynch Credit Conference
6. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
7. WebMD to Present at the Citi 7th Annual U.S. Small/Mid Cap Conference
8. ERT to Present at Lazard Capital Markets 7th Annual Healthcare Conference on November 16, 2010
9. InfraReDx Announces Presentation of LipiScan™ Research at American Heart Association Scientific Sessions 2010
10. Philips and American Heart Association Present Fourth Annual Resuscitation Fellowship Award
11. HeartWare to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... April 19, 2017  SARES•REGIS Group leased the ... developing at Conejo Spectrum Business Park in ... Atara Biotherapeutics, Inc. , a biopharmaceutical company developing ... diseases that have been underserved by scientific innovation, ... for cancer, autoimmune and infectious disease. ...
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, ... on providing the Urology, Uro/Gyn and Gynecology markets with ... the first quarter ended March 31, 2017 after the ... The Company will host a conference call and ... on Tuesday, May 2, 2017 at 4:30 p.m. Eastern ...
(Date:4/18/2017)... 18, 2017 Research and Markets has announced ... report to their offering. ... global arthroscopy devices market to grow at a CAGR of 6.35% ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
Breaking Medicine Technology:
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... ... specifically to improve the profitability of ready-to-drink, high-protein beverages by helping beverage manufacturers ... alternative to dairy proteins, providing direct cost savings as well as more stable ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... and collaboration, announces Mirroring360 Pro . This new addition to the Mirroring360 ... experience for education and business. , Mirroring360 Pro enables educators, business professionals and ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... CEOs, CFOs and HR decision-makers are preparing for how his administration could impact ... will provide insight into what changes are most likely to make it through ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... a modern procedure that achieves results in a fraction of the time as ... Vegas, NV, with Significance Dental Specialists, now offers this revolutionary treatment with or ...
(Date:4/25/2017)... MN (PRWEB) , ... April 25, 2017 , ... Buyers ... and recreational users to dispensaries and head shops –can’t help but be heartened by ... for the tell-tale cannabis odor aptly described as “skunk smell.” At last they ...
Breaking Medicine News(10 mins):